Our Vision

Genesis Theranostix Group aims to provide the 

best-in-class first trimester screening test and prevent the development of preeclampsia.

Our Scientists

current or former section heads at NIH discovered new disease pathways of preeclampsia using advanced systems biology tools, and developed a novel platform for the early and accurate diagnosis.

Our Group

headquartered in Budapest and San Diego uses this IP to develop a first trimester screening test to enable early and  personalized preventive therapies.